EMT is the dominant program in human colon cancer
Andre Loboda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Timothy J. Yeatman(University of South Florida), Rob A.�E.�M. Tollenaar(Leiden University Medical Center), Peter Shaw(Wenzhou Medical University), Carolyne A Buser(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Nebozhyn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Deepak Agrawal(All India Institute of Medical Sciences), Pearl S. Huang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hongyue Dai(Rosetta Stone (United States)), Laura van’t Veer(University of California, San Francisco), David Jackson(The Honourable Society of Lincoln's Inn), James Watters(Sanofi (France))
Cited by 278
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition
|New England Journal of Medicine|2004|1.7k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k